Avalo to Present at the H.C. Wainwright Global Life Sciences Conference
Avalo Therapeutics (Nasdaq: AVTX) will have its CEO, Garry A. Neil, present virtually at the H.C. Wainwright Global Life Sciences Conference from May 23-26, 2022. The pre-recorded presentation will be available on May 24, 2022, at 7:00 AM ET. Investors can access the webcast on the company's website under the 'News/Events' section. Avalo is focused on developing targeted therapeutics for significant unmet clinical needs, particularly in immunology and rare genetic diseases, with a diverse portfolio aimed at delivering meaningful medical impact.
- None.
- None.
WAYNE, Pa. and ROCKVILLE, Md., May 17, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will present virtually at the H.C. Wainwright Global Life Sciences Conference being held May 23-26, 2022. The pre-recorded formal presentation will be made available on Tuesday, May 24, 2022 at 7:00 AM ET.
A webcast of the pre-recorded presentation can be accessed under the “News/Events” page in the Investors section of the Company’s website, www.avalotx.com.
About Avalo Therapeutics
Avalo Therapeutics is a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology and rare genetic diseases. The Company has built a diverse portfolio of innovative therapies to deliver meaningful medical impact for patients in urgent need. The Company’s clinical candidates commonly have a proven mechanistic rationale, biomarkers and/or an established proof-of-concept to expedite and increase the probability of success.
For more information about Avalo, please visit www.avalotx.com.
Forward-Looking Statements
This press release may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Avalo’s control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to Avalo’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “might,” “will,” “could,” “would,” “should,” “continue,” “seeks,” “aims,” “predicts,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” or similar expressions (including their use in the negative), or by discussions of future matters such as: the future financial and operational outlook; the development of product candidates or products; timing and success of trial results and regulatory review; potential attributes and benefits of product candidates; and other statements that are not historical. These statements are based upon the current beliefs and expectations of Avalo’s management but are subject to significant risks and uncertainties, including: Avalo's cash position and the potential need for it to raise additional capital; drug development costs, timing and other risks, including reliance on investigators and enrollment of patients in clinical trials, which might be slowed by the COVID-19 pandemic; reliance on key personnel, including as a result of recent management changes; regulatory risks; general economic and market risks and uncertainties, including those caused by the COVID-19 pandemic and tensions in Ukraine; and those other risks detailed in Avalo’s filings with the SEC. Actual results may differ from those set forth in the forward-looking statements. Except as required by applicable law, Avalo expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Avalo’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
For investor inquiries
Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
csullivan@avalotx.com
410-803-6793
or
Chris Brinzey
ICR Westwicke
Chris.brinzey@westwicke.com
339-970-2843
FAQ
When will Avalo Therapeutics present at the H.C. Wainwright Conference?
How can I access Avalo Therapeutics' presentation?
What is Avalo Therapeutics' focus in the biotech sector?
What does Avalo Therapeutics do?
What stock symbol represents Avalo Therapeutics?
